Bristol-Myers Squibb cefadroxil patent
Executive SummaryWas infringed by Moleculon's Kalipharma unit, the New Jersey Federal Court rules June 15. The drug accounted for about one-fourth of Kalipharma's sales revenue, before the firm suspended its sale in May following an International Trade Commission decision barring import of the drug. Moleculon said it will appeal the patent decision. Zenith and Biocraft recently reached a settlement of regarding a similar patent suit brought by Bristol-Myers Squibb ("The Pink Sheet" April 2, T&G-12).
You may also be interested in...
AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.
The US agency is engaged with an ethylene oxide (EtO) sterilizer in Illinois that has temporarily closed to determine if there are any potential risks to the medical device supply chain. While the plant shut down about a month ago, regulators have only recently been made aware of the decision, which resulted from a law passed last year by the state legislature.
Pfizer's biosimilar franchise is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.